EVE — Evolva Holding Share Price
Last trade - 00:00- CH₣8.51m
- CH₣1.76m
- 13
- 87
- 85
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.29 | ||
| Price to Tang. Book | 1.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | 1.8 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.81% | ||
| Return on Equity | 17.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 7.54 | 9.88 | 15.54 | 9.44 | n/a | 32.66 | 60.9 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evolva Holding Ltd is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.
Directors
- Beat In-Albon NEC (69)
- Oliver Walker CEO (52)
- Andre Pennartz CFO (47)
- Richard Ridinger NED (63)
- Stephan Schindler NED (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 18th, 1997
- Public Since
- May 4th, 2005
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 7,211,552
- Address
- Duggingerstrasse 23, REINACH, 4153
- Web
- https://www.evolva.com/
- Phone
- +41 614852000
- Auditors
- Forvis Mazars
Upcoming Events for EVE
Similar to EVE
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
FAQ
As of Today at 20:33 UTC, shares in Evolva Holding are trading at CH₣1.18. This share price information is delayed by 15 minutes.
Shares in Evolva Holding last closed at CH₣1.18 and the price had moved by +25.27% over the past 365 days. In terms of relative price strength the Evolva Holding share price has outperformed the FTSE Global All Cap Index by +23.06% over the past year.
The overall consensus recommendation for Evolva Holding is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEvolva Holding does not currently pay a dividend.
Evolva Holding does not currently pay a dividend.
Evolva Holding does not currently pay a dividend.
To buy shares in Evolva Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣1.18, shares in Evolva Holding had a market capitalisation of CH₣8.51m.
Here are the trading details for Evolva Holding:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: EVE
Based on an overall assessment of its quality, value and momentum Evolva Holding is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Evolva Holding is CH₣70.00. That is 5832.2% above the last closing price of CH₣1.18.
Analysts covering Evolva Holding currently have a consensus Earnings Per Share (EPS) forecast of -CH₣1.12 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evolva Holding. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +37.55%.
As of the last closing price of CH₣1.18, shares in Evolva Holding were trading +18.62% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Evolva Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Evolva Holding's management team is headed by:
- Beat In-Albon - NEC
- Oliver Walker - CEO
- Andre Pennartz - CFO
- Richard Ridinger - NED
- Stephan Schindler - NED